NABEEL UWAYDAH: Open Payments
NPI 1750602678 · AURORA, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$986 in 54 payments from 19 companies in 2025. Trend: 2023 $107 · 2024 $128 · 2025 $986
Food & beverage: $986
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $157 |
| Indivior Inc. | 8 | $144 |
| AstraZeneca Pharmaceuticals LP | 6 | $117 |
| ViiV Healthcare Company | 4 | $86 |
| Astellas Pharma US Inc | 3 | $69 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| Alkermes, Inc. | 3 | $59 |
| Teva Pharmaceuticals USA, Inc. | 3 | $54 |
| Novo Nordisk Inc | 2 | $33 |
| Seqirus USA Inc | 1 | $28 |
Products named: CAPLYTA, SUBLOCADE, APRETUDE, Veozah, REXULTI, AIRSUPRA, UZEDY, VIVITROL.
Industry payments across CO — which companies pay providers there.
